|
1
|
Chiorazzi N, Rai KR and Ferrarini M:
Chronic lymphocytic leukemia. N Engl J Med. 352:804–815. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fernando TR, Rodriguez-Malave NI and Rao
DS: MicroRNAs in B cell development and malignancy. J Hematol
Oncol. 5:72012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Martini V, Frezzato F, Severin F, Raggi F,
Trimarco V, Martinello L, Molfetta R, Visentin A, Facco M,
Semenzato G, et al: Abnormal regulation of BCR signalling by c-Cbl
in chronic lymphocytic leukaemia. Oncotarget. 9:32219–32231. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rajendran V: Structural analysis of
oncogenic mutation of isocitrate dehydrogenase 1. Mol Biosyst.
12:2276–2287. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rajendran V, Gopalakrishnan C and
Sethumadhavan R: Pathological role of a point mutation (T315I) in
BCR-ABL1 protein-A computational insight. J Cell Biochem.
119:918–925. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Luo P, Yang Q, Cong LL, Wang XF, Li YS,
Zhong XM, Xie RT, Jia CY, Yang HQ, Li WP, et al: Identification of
miR124a as a novel diagnostic and prognostic biomarker in nonsmall
cell lung cancer for chemotherapy. Mol Med Rep. 16:238–246. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kamaraj B, Gopalakrishnan C and Purohit R:
In silico analysis of miRNA-mediated gene regulation in OCA and OA
genes. Cell Biochem Biophys. 70:1923–1932. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang Y, Han X, Wu H and Zhou Y:
Bioinformatics analysis of transcription profiling of solid
pseudopapillary neoplasm of the pancreas. Mol Med Rep.
16:1635–1642. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vogelstein B, Papadopoulos N, Velculescu
VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes.
Science. 339:1546–1558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lim L, Lau N, Garrett-Engele P, Grimson A,
Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM:
Microarray analysis shows that some microRNAs downregulate large
numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bhaumik P, Gopalakrishnan C, Kamaraj B and
Purohit R: Single nucleotide polymorphisms in microRNA binding
sites: Implications in colorectal cancer. ScientificWorldJournal.
2014:5471542014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gutierrez A Jr, Tschumper RC, Wu X,
Shanafelt TD, Eckel-Passow J, Huddleston PM III, Slager SL, Kay NE
and Jelinek DF: LEF-1 is a prosurvival factor in chronic
lymphocytic leukemia and is expressed in the preleukemic state of
monoclonal B-cell lymphocytosis. Blood. 116:2975–2983. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vallat L, Kemper CA, Jung N,
Maumy-Bertrand M, Bertrand F, Meyer N, Pocheville A, Fisher JW III,
Gribben JG and Bahram S: Reverse-engineering the genetic circuitry
of a cancer cell with predicted intervention in chronic lymphocytic
leukemia. Proc Natl Acad Sci USA. 110:459–464. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ruiz-Lafuente N, Alcaraz-García MJ,
Sebastián-Ruiz S, García-Serna AM, Gómez-Espuch J, Moraleda JM,
Minguela A, García-Alonso AM and Parrado A: IL-4 up-regulates
MiR-21 and the MiRNAs hosted in the CLCN5 gene in chronic
lymphocytic leukemia. PLoS One. 10:e01249362015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Szklarczyk D, Franceschini A, Wyder S,
Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos
A, Tsafou KP, et al: STRING v10: Protein-protein interaction
networks, integrated over the tree of life. Nucleic Acids Res.
43:D447–D452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wong N and Wang X: miRDB: An online
resource for microRNA target prediction and functional annotations.
Nucleic Acids Res. 43:D146–D152. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chou CH, Shrestha S, Yang CD, Chang NW,
Lin YL, Liao KW, Huang WC, Sun TH, Tu SJ, Lee WH, et al: miRTarBase
update 2018: A resource for experimentally validated
microRNA-target interactions. Nucleic Acids Res. 46:D296–D302.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nabhan C and Rosen ST: Chronic lymphocytic
leukemia: A clinical review. JAMA. 312:2265–2276. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cang S, Iragavarapu C, Savooji J, Song Y
and Liu D: ABT-199 (venetoclax) and BCL-2 inhibitors in clinical
development. J Hematol Oncol. 8:1292015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rai KR: Therapeutic potential of new B
cell-targeted agents in the treatment of elderly and unfit patients
with chronic lymphocytic leukemia. J Hematol Oncol. 8:852015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kwok M, Davies N, Agathanggelou A, Smith
E, Oldreive C, Petermann E, Stewart G, Brown J, Lau A, Pratt G, et
al: ATR inhibition induces synthetic lethality and overcomes
chemoresistance in TP53 or ATM defective chronic lymphocytic
leukemia cells. Blood. 127:582–595. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen F, Shen C, Wang X, Wang H, Liu Y, Yu
C, Lv J, He J and Wen Z: Identification of genes and pathways in
nasopharyngeal carcinoma by bioinformatics analysis. Oncotarget.
8:63738–63749. 2017.PubMed/NCBI
|
|
26
|
Sun C, Yuan Q, Wu D, Meng X and Wang B:
Identification of core genes and outcome in gastric cancer using
bioinformatics analysis. Oncotarget. 8:70271–70280. 2017.PubMed/NCBI
|
|
27
|
Zhou YY, Li Y, Jiang WQ and Zhou LF:
MAPK/JNK signalling: A potential autophagy regulation pathway.
Biosci Rep. 35:e001992015.PubMed/NCBI
|
|
28
|
Shukla A, Shukla V and Joshi SS:
Regulation of MAPK signaling and implications in chronic
lymphocytic leukemia. Leuk Lymphoma. 59:1565–1573. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pandzic T, Larsson J, He L, Kundu S, Ban
K, Akhtar-Ali M, Hellström AR, Schuh A, Clifford R, Blakemore SJ,
et al: Transposon mutagenesis reveals fludarabine resistance
mechanisms in chronic lymphocytic leukemia. Clin Cancer Res.
22:6217–6227. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
He X and Zhang J: Why do hubs tend to be
essential in protein networks? PLoS Genet. 2:e882006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Barabási A and Oltvai Z: Network biology:
Understanding the cell's functional organization. Nat Rev Genet.
5:101–113. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hahn M and Kern A: Comparative genomics of
centrality and essentiality in three eukaryotic protein-interaction
networks. Mol Biol Evol. 22:803–806. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fisher KW, Montironi R, Lopez Beltran A,
Moch H, Wang L, Scarpelli M, Williamson SR, Koch MO and Cheng L:
Molecular foundations for personalized therapy in prostate cancer.
Curr Drug Targets. 16:103–114. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu X, Liu D, Tao D, Xiang W, Xiao X, Wang
M, Wang L, Luo G, Li Y, Zeng F and Jiang G: BRD4 regulates EZH2
transcription through upregulation of C-MYC and represents a novel
therapeutic target in bladder cancer. Mol Cancer Ther.
15:1029–1042. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sánchez-Beato M, Sánchez-Aguilera A and
Piris MA: Cell cycle deregulation in B-cell lymphomas. Blood.
101:1220–1235. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Delgado MD and León J: Myc roles in
hematopoiesis and leukemia. Genes Cancer. 1:605–616. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vaux DL, Cory S and Adams JM: Bcl-2 gene
promotes haemopoietic cell survival and cooperates with c-myc to
immortalize pre-B cells. Nature. 335:440–442. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dawson SJ, Makretsov N, Blows FM, Driver
KE, Provenzano E, Le Quesne J, Baglietto L, Severi G, Giles GG,
McLean CA, et al: BCL2 in breast cancer: A favourable prognostic
marker across molecular subtypes and independent of adjuvant
therapy received. Br J Cancer. 103:668–675. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cheng H, Wang X, Li T and Chen L: Bcl-2
expression and patient survival in gastric cancer: A systematic
review of the literature with meta-analysis. Med Oncol. 32:3892015.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Strasser A, Harris AW, Bath ML and Cory S:
Novel primitive lymphoid tumours induced in transgenic mice by
cooperation between myc and bcl-2. Nature. 348:331–333. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Landau D, Tausch E, Taylor-Weiner A,
Stewart C, Reiter JG, Bahlo J, Kluth S, Bozic I, Lawrence M,
Böttcher S, et al: Mutations driving CLL and their evolution in
progression and relapse. Nature. 526:525–530. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Robertson L, Plunkett W, McConnell K,
Keating M and McDonnell T: Bcl-2 expression in chronic lymphocytic
leukemia and its correlation with the induction of apoptosis and
clinical outcome. Leukemia. 10:456–459. 1996.PubMed/NCBI
|
|
43
|
Kaser A, Zeissig S and Blumberg RS:
Inflammatory bowel disease. Annu Rev Immunol. 28:573–621. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wierda WG, Johnson MM, Do KA, Manshouri T,
Dey A, O'Brien S, Giles FJ, Kantarjian H, Thomas D, Faderl S, et
al: Plasma interleukin 8 level predicts for survival in chronic
lymphocytic leukaemia. Br J Haematol. 120:452–456. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Slevin M, Krupinski J, Gaffney J, Matou S,
West D, Delisser H, Savani RC and Kumar S: Hyaluronan-mediated
angiogenesis in vascular disease: Uncovering RHAMM and CD44
receptor signaling pathways. Matrix Biol. 26:58–68. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chang G, Zhang H, Wang J, Zhang Y, Xu H,
Wang C, Zhang H, Ma L, Li Q and Pang T: CD44 targets Wnt/β-catenin
pathway to mediate the proliferation of K562 cells. Cancer Cell
Int. 13:1172013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Krause DS, Lazarides K, von Andrian UH and
Van Etten RA: Requirement for CD44 in homing and engraftment of
BCR-ABL-expressing leukemic stem cells. Nat Med. 12:1175–1180.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wang Y, Yang J, Li J, Wang RC, Yuan J, Li
Y, Wang SY, Wang C and Hao HL: Effect of arsenic trioxide on K562
cell proliferation and its mechanism. Zhongguo Shi Yan Xue Ye Xue
Za Zhi. 25:90–93. 2017.(In Chinese). PubMed/NCBI
|
|
49
|
Yang WF and WANG FZ: Expression of CD1a,
CD80, CD86 in dendritic cell of tumor tissue and regional lymph
node in esophageal carcinoma. Ai Zheng. 23:189–192. 2004.(In
Chinese). PubMed/NCBI
|
|
50
|
Montresor A, Toffali L, Mirenda M, Rigo A,
Vinante F and Laudanna C: JAK2 tyrosine kinase mediates integrin
activation induced by CXCL12 in B-cell chronic lymphocytic
leukemia. Oncotarget. 6:34245–34257. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Tefferi A and Pardanani A: JAK inhibitors
in myeloproliferative neoplasms: Rationale, current data and
perspective. Blood Rev. 25:229–237. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang HY and Zhai XW: Research advances in
the role of JAK2 mutations in acute leukemia. Zhongguo Dang Dai Er
Ke Za Zhi. 17:644–649. 2015.(In Chinese). PubMed/NCBI
|
|
53
|
Blahna MT and Hata A: Smad-mediated
regulation of microRNA biosynthesis. FEBS Lett. 586:1906–1912.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Fabregat I, Moreno-Càceres J, Sànchez A,
Dooley S, Dewidar B, Giannelli G and Ten Dijke P: IT-LIVER
Consortium: TGF-β signalling and liver disease. FEBS J.
283:2219–2232. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Serafin V, Lissandron V, Buldini B,
Bresolin S, Paganin M, Grillo F, Andriano N, Palmi C, Cazzaniga G,
Marmiroli S, et al: Phosphoproteomic analysis reveals
hyperactivation of mTOR/STAT3 and LCK/Calcineurin axes in pediatric
early T-cell precursor ALL. Leukemia. 31:1007–1011. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ban K, Gao Y, Amin HM, Howard A, Miller C,
Lin Q, Leng X, Munsell M, Bar-Eli M, Arlinghaus RB and Chandra J:
BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous
leukemia. Blood. 111:2904–2908. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Chen L, Widhopf G, Huynh L, Rassenti L,
Rai KR, Weiss A and Kipps TJ: Expression of ZAP-70 is associated
with increased B-cell receptor signaling in chronic lymphocytic
leukemia. Blood. 100:4609–4614. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Orchard JA, Ibbotson RE, Davis Z, Wiestner
A, Rosenwald A, Thomas PW, Hamblin TJ, Staudt LM and Oscier DG:
ZAP-70 expression and prognosis in chronic lymphocytic leukaemia.
Lancet. 363:105–111. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Purroy N, Abrisqueta P, Carabia J, Carpio
C, Palacio C, Bosch F and Crespo M: Co-culture of primary CLL cells
with bone marrow mesenchymal cells, CD40 ligand and CpG ODN
promotes proliferation of chemoresistant CLL cells phenotypically
comparable to those proliferating in vivo. Oncotarget. 6:7632–7643.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kolla V, Gonzales L, Gonzales J, Wang P,
Angampalli S, Feinstein SI and Ballard PL: Thyroid transcription
factor in differentiating type II cells: Regulation, isoforms, and
target genes. Am J Respir Cell Mol Biol. 36:213–225. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Durchdewald M, Angel P and Hess J: The
transcription factor Fos: A Janus-type regulator in health and
disease. Histol Histopathol. 24:1451–1461. 2009.PubMed/NCBI
|
|
62
|
Wagstaff SC, Bowler WB, Gallagher JA and
Hipskind RA: Extracellular ATP activates multiple signalling
pathways and potentiates growth factor-induced c-fos gene
expression in MCF-7 breast cancer cells. Carcinogenesis. 2175–2181.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zhao L, Shan Y, Liu B, Li Y and Jia L:
Functional screen analysis reveals miR-3142 as central regulator in
chemoresistance and proliferation through activation of the
PTEN-AKT pathway in CML. Cell Death Dis. 8:e28302017. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Chiang HR, Schoenfeld LW, Ruby JG, Auyeung
VC, Spies N, Baek D, Johnston WK, Russ C, Luo S, Babiarz JE, et al:
Mammalian microRNAs: Experimental evaluation of novel and
previously annotated genes. Genes Dev. 24:992–1009. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Cao T, Li H, Hu Y, Ma D and Cai X: miR-144
suppresses the proliferation and metastasis of hepatocellular
carcinoma by targeting E2F3. Tumour Biol. 35:10759–10764. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Wang H, Wang A, Hu Z, Xu X, Liu Z and Wang
Z: A critical role of miR-144 in diffuse large B-cell lymphoma
proliferation and invasion. Cancer Immunol Res. 4:337–344. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Machová Poláková K, Lopotová T, Klamová H,
Burda P, Trněný M, Stopka T and Moravcová J: Expression patterns of
microRNAs associated with CML phases and their disease related
targets. Mol Cancer. 10:412011. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Tomioka A, Tanaka N, Yoshikawa M, Miyake
M, Anai S, Chihara Y, Okajima E, Hirayama A, Hirao Y and Fujimoto
K: Nadir PSA level and time to nadir PSA are prognostic factors in
patients with metastatic prostate cancer. BMC Urol. 14:332014.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Song B, Long Y, Liu D, Zhang W and Liu C:
MicroRNA-582 promotes tumorigenesis by targeting phosphatase and
tensin homologue in colorectal cancer. Int J Mol Med. 40:867–874.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Fang L, Cai J, Chen B, Wu S, Li R, Xu X,
Yang Y, Guan H, Zhu X, Zhang L, et al: Aberrantly expressed
miR-582-3p maintains lung cancer stem cell-like traits by
activating Wnt/β-catenin signalling. Nat Commun. 6:86402015.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Maeno A, Terada N, Uegaki M, Goto T, Okada
Y, Kobayashi T, Kamba T, Ogawa O and Inoue T: Up-regulation of
miR-582-5p regulates cellular proliferation of prostate cancer
cells under androgen-deprived conditions. Prostate. 74:1604–1612.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Uchino K, Takeshita F, Takahashi RU,
Kosaka N, Fujiwara K, Naruoka H, Sonoke S, Yano J, Sasaki H, Nozawa
S, et al: Therapeutic effects of microRNA-582-5p and −3p on the
inhibition of bladder cancer progression. Mol Ther. 21:610–619.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Lafage-Pochitaloff M, Courcoul M,
Simonetti J, Sainty D, Dastugue N, Tabilio A, Hagemeijer A and Birg
F: Expression of the ETS2 and transferrin receptor genes in
Philadelphia-positive chronic myeloid leukemia patients with a
reciprocal t(3;21). Genes Chromosomes Cancer. 5:1–13. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Zhu DX, Miao KR, Fang C, Fan L, Zhu W, Zhu
HY, Zhuang Y, Hong M, Liu P, Xu W and Li JY: Aberrant microRNA
expression in Chinese patients with chronic lymphocytic leukemia.
Leuk Res. 35:730–734. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Artavanis-Tsakonas S, Rand MD and Lake RJ:
Notch signaling: Cell fate control and signal integration in
development. Science. 284:770–776. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Hubmann R, Schwarzmeier JD, Shehata M,
Hilgarth M, Duechler M, Dettke M and Berger R: Notch2 is involved
in the overexpression of CD23 in B-cell chronic lymphocytic
leukemia. Blood. 99:3742–3747. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Song HM, Luo Y, Li DF, Wei CK, Hua KY,
Song JL, Xu H, Maskey N and Fang L: MicroRNA-96 plays an oncogenic
role by targeting FOXO1 and regulating AKT/FOXO1/Bim pathway in
papillary thyroid carcinoma cells. Int J Clin Exp Pathol.
8:9889–9900. 2015.PubMed/NCBI
|
|
78
|
Chruścik A and Lam AK: Clinical
pathological impacts of microRNAs in papillary thyroid carcinoma: A
crucial review. Exp Mol Pathol. 99:393–398. 2015. View Article : Google Scholar : PubMed/NCBI
|
